Skip to main content

Table 4 Unadjusted odds of completing M6 in 1011 participants by baseline patient characteristics and other variables

From: The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients

Patient characteristics

Univariate analysis

ORa

95% CIb

P

Gender

  Female

—

—

 

  Male

0.93

0.72, 1.20

0.587

Education

  College or lower

—

—

 

  High school or lower

0.86

0.67, 1.11

0.252

Marital status

  Married/living as married

—

—

 

  Single/divorced/widowed/separated

0.83

0.64, 1.06

0.140

Age

  < 55

—

—

 

  ≥ 55

1.21

0.94, 1.57

0.135

Used cannabis for any reason 5 or more times in the last 12 months

  No

—

—

 

  Yes

0.93

0.72, 1.20

0.579

Primary illness or medical condition you currently treat with medical cannabis

  Pain

—

—

 

  Mental health issues

0.79

0.52, 1.20

0.275

  Insomnia

0.98

0.54, 1.77

0.942

  Other

0.94

0.56, 1.57

0.805

Use of opioid

  N

—

—

 

  Y

0.69

0.52, 0.92

0.011

Use of non-opioid pain medications

  N

—

—

 

  Y

1.13

0.83, 1.53

0.439

Use of benzodiazepine

  N

—

—

 

  Y

1.32

0.81, 2.18

0.269

Use of antidepressant

  N

—

—

 

  Y

1.52

1.09, 2.13

0.014

Use of anti-seizure

  N

—

—

 

  Y

1.68

1.19, 2.36

0.003

Opioid—dose per day (DDD)

  > 0, < 0.57

—

—

 

  ≥ 0.57

0.67

0.38, 1.17

0.157

Non-opioid pain medications—dose per day (DDD)

  > 0, < 0.43

—

—

 

  ≥ 0.43

0.72

0.39, 1.33

0.289

Benzodiazepine—dose per day (DDD)

  > 0, < 0.38

—

—

 

   ≥ 0.38

1.54

0.54, 4.42

0.423

Antidepressant—dose per day (DDD)

  > 0, < 1

—

—

 

  ≥ 1

1.50

0.68, 3.31

0.316

Anti-seizure—dose per day (DDD)

  > 0, < 0.5

—

—

 

  ≥ 0.5

0.82

0.39, 1.72

0.60

WHOQOL—physical health (baseline)

  < 36

—

—

 

  ≥ 36

1

0.78, 1.28

0.981

WHOQOL—psychological (baseline)

  < 54

—

—

 

  ≥ 54

1.33

1.03, 1.71

0.028

WHOQOL—social relationships (baseline)

  < 58

—

—

 

  ≥ 58

1.23

0.95, 1.60

0.114

WHOQOL—environment (baseline)

  < 66

—

—

 

  ≥ 66

1.15

0.89, 1.47

0.289

Cannabis use per week (g)

  < 5

—

—

 

  ≥ 5

1.06

0.83, 1.36

0.645

Frequency of cannabis use per week

   

  < 14

—

—

 

  ≥ 14

1.11

0.87, 1.44

0.401

Currently using Tilray extract products

  N

—

—

 

  Y

0.91

0.70, 1.18

0.479

Preferred type of cannabis

  CBD

—

—

 

  THC

1.29

0.94, 1.78

0.113

  No preference

1.56

1.16, 2.10

0.004

Primary method of use

  Inhaled

—

—

 

  Orally ingested

0.72

0.56, 0.93

0.012

Enrollment period

  Enrolled prior to 17 April 2018 (M6 would be pre-legalization)

—

—

 

  Enrolled between 17 April and 15 July 2018 (M6 would be post legalization)

0.32

0.22, 0.46

 < 0.001

  1. aOR  Odds ratio, bCI Confidence interval